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Group A Streptococcus (GAS; Streptococcus pyogenes) is a bacterial pathogen for which  52 
a vaccine is not available1,2. Employing the advantages of high-throughput DNA 53 
sequencing technology to vaccine design, we have analysed 1,579 GAS genomes from 54 
isolates causing significant morbidity and mortality in both developing and high-income 55 
countries. The global GAS population structure reveals extensive genomic heterogeneity 56 
overlaid with high levels of accessory gene plasticity. We identified the existence of more 57 
than 200 clinically associated genomic phylogroups across 18 geographical regions, 58 
highlighting challenges in designing vaccines of global utility. We report the extent of 59 
natural genetic diversity across 141 GAS molecular emm types3, 399 multi-locus 60 
sequence types4 and 37 M-protein clusters5. To determine vaccine candidate coverage, 61 
we investigated all previously described GAS antigens2,6 for gene carriage and gene 62 
sequence heterogeneity. Only 15 of 28 vaccine antigen candidates were found to have 63 
both low naturally occurring sequence variation and high (>98%) coverage across this 64 
diverse GAS population. Mapping global antigenic heterogeneity onto antigen protein 65 
structure provides a new approach for the identification of conserved epitopes on the 66 
surface of vaccine antigens. This technological platform for vaccine coverage 67 
determination is equally applicable to prospective GAS antigens identified in future 68 
studies.  69 
 70 
GAS causes >700 million cases per year of superficial diseases such as pharyngitis and 71 
impetigo, and >600,000 cases per year of serious invasive infection. Immune sequelae such 72 
as acute rheumatic fever (ARF) and acute post-streptococcal glomerulonephritis each account 73 
for >400,000 cases per year1,2. As a consequence of ARF, >30 million people live with 74 
rheumatic heart disease, involving mitral and/or aortic regurgitation7. GAS ranks within the 75 
top 10 infectious disease causes of human mortality worldwide1. Despite over 100 years of 76 
research, a commercial vaccine has not been developed2. Obstacles that have hindered 77 
development of a GAS vaccine include serotype diversity, GAS antigen carriage and 78 
variation, and vaccine safety concerns due to the immune sequelae caused by repeated GAS 79 
infection2,6. In 1978 the US Food and Drug Administration imposed a moratorium on human 80 
GAS vaccine trials due to concerns surrounding the potential of vaccine antigens to trigger 81 
autoimmunity. The US National Institute of Allergy and Infectious Diseases convened an 82 
expert workshop in 2004, which led to the lifting of the ban, but noted the possible 83 
involvement of M protein and group A carbohydrate antigens in autoimmunity8. A limited 84 
number of phase 1 clinical trials have since been conducted, focused primarily on multivalent 85 
N-terminal M protein vaccine candidates9,10. Other candidate GAS vaccine antigens that have 86 
demonstrated efficacy in animal models include the J8 peptide incorporated in the C-terminal 87 
repeats of M protein11, and non-M protein candidate vaccine antigens. The group A 88 
carbohydrate12,13 and multiple other surface or secreted proteins have been examined in 89 
preclinical vaccine studies (Supplementary Table 1)2,6. While a number of GAS antigens 90 
have been selected to avoid autoimmune concerns14,15 or specifically engineered to remove 91 
potential autoimmune-involved epitopes11,13, the capacity to investigate issues of serotype 92 
diversity, antigen carriage and antigenic variation is impeded by the tremendous genetic 93 
diversity within the global GAS population16. To address this issue, we have developed a 94 
compendium of all GAS vaccine antigen sequences from 1,579 isolates employing high-95 
throughput genomic technology. 96 
 97 
  98 
RESULTS 99 
  100 
GAS population genetics 101 
We have compiled the most geographically and clinically diverse database of GAS genome 102 
sequences to date, comprising 1,579 strains, of which 645 isolates are reported for the first 103 
time (Supplementary Table 2). Our sampling strategy targeted geographical regions where 104 
GAS infection is endemic and encompassed isolates from both asymptomatic carriage and 105 
various clinical disease states. We included population-based studies from published 106 
databases and a limited number of representative isolates from emm-type specific 107 
microevolution studies, to prevent substantial epidemiological bias in data interpretation. 108 
Extracting the classical GAS epidemiological and genotypic markers of differentiation from 109 
1,579 genome assemblies, the database constitutes 141 emm types (259 emm sub-types), 37 110 
M-protein clusters and 399 multi-locus sequence types (MLSTs).  111 
 112 
To assess the genome-wide relationships within this global database, we identified the core 113 
genome of GAS to be 1,325 coding DNA sequences (CDS), based on an 80% nucleotide 114 
sequence coverage threshold and presence in >99% of the 1,579 genomes (Supplementary 115 
Table 3). To examine signatures of recombination within the core 1,325 genes, we analysed 116 
each core gene separately for evidence of mosaicism using the homologous recombination 117 
detection tool fastGEAR17. Using this algorithm, we estimated 841 core genes as having a 118 
recombinatorial evolutionary history (Supplementary Fig. 1), leaving 484 non-119 
recombinogenic core genes (Supplementary Table 3) encoded by 309,723 bp of sequence  120 
(~17% of a complete GAS genome). This is likely to be an underrepresentation of the total 121 
levels of GAS core genome recombination based on the limitations in sampling (for example, 122 
the potential of a donor genome not being represented in the collection) and/or the limitation 123 
that larger blocks of recombination encompassing multiple genes may be missed. A pseudo-124 
core sequence alignment was generated using these 484 core GAS genes. After removal of 125 
repeat sequences that can confound read mapping, a total of 33,917 single nucleotide 126 
polymorphisms (SNPs) were identified within a 308,108 bp pseudo-reference. Phylogenetic 127 
analysis of the 484 gene pseudo-core GAS genome identified a deep branching star-like 128 
population structure indicative of an early radiation of GAS into distinct lineages (Fig. 1a). 129 
While the overall branching topology of the tree is supported by comparing genome-specific 130 
and lineage-specific SNPs (Supplementary Fig. 2), low bootstrap support towards the 131 
polytomous root of the tree prevents accurate inferences regarding the evolutionary 132 
relationships of the lineage-specific radiations (Fig 1a). Comparative analyses of the core 133 
phylogenetic tree topologies prior (1,325 genes) and post (484 genes) removal of the 134 
predicted recombinogenic CDS, did not affect the overall clustering of the isolates at the 135 
terminal branches of the tree (Supplementary Fig. 3), indicating that recombination events 136 
within the ‘core’ GAS genome have blurred the ancestral evolutionary relationships between 137 
GAS lineages, yet have not introduced sufficient homoplasy to disrupt recent evolutionary 138 
signals.  139 
 140 
Applying a phylogenetic clustering approach (RAMI18) to the refined core 484 gene 141 
alignment, we identified 250 distinct genetic clusters of evolutionarily related lineages, herein 142 
termed phylogroups (Supplementary Fig. 4a). The median nucleotide divergence between 143 
phylogroups was 0.52% (range 0.29 – 0.62%), whereas genomes within the same phylogroup 144 
differed by a median divergence of 0.02% (range 0 – 0.13%). Of the 247 phylogroups, 178 145 
phylogroups were represented by 2 or more isolates. Overlaying the geographical origin of 146 
the isolates suggests that over half these 178 phylogroups have a diverse geographical 147 
distribution (Fig. 1a). The maintenance of so many distinct genetic lineages of GAS not 148 
appearing to be restricted by geographical boundaries is suggestive of extensive genetic drift 149 
within the human adapted host or independent adaptive selection. Furthermore, these lineages 150 
do not appear to be restricted by clinical association (Supplementary Fig. 4b). For example, 151 
137 of the 178 phylogroups (77%) contain a clinically defined invasive GAS isolate, defined 152 
in this study as an isolate obtained from a normally sterile site. Examination of the 153 
distribution of the classic GAS molecular epidemiological markers relative to the 178 multi-154 
isolate phylogroups, revealed that 144 (81%) carried a single emm sequence type, 121 (68%) 155 
carried a single emm sub-type and 70 (39%) were of a single multi-locus sequence type 156 
(Supplementary Fig. 5).  Only 23 (13%) of the emm sequence types and 56 (31%) of the emm 157 
sub-types were unique to a single phylogroup of 2 or more strains, inferring extensive 158 
heterogeneity within GAS emm types. To further investigate these associations, we plotted 159 
the pairwise genetic distance of isolates based on common GAS epidemiological markers 160 
(emm type, emm sub-type, and MLST). Greater than 66% of emm types (80/121 multi-isolate 161 
representatives) and 35% of the emm sub-types (57/176 multi-isolate representatives) 162 
exceeded the minimal median nucleotide divergence between phylogroups (0.29% which 163 
equates to ~900 SNPs within 484 core genes), showing that many emm types and emm sub-164 
types do not share a close evolutionary history and in many cases represent different genetic 165 
lineages (Supplementary Fig. 6). Similarly, 17% of MLST (38/221 multi-isolate 166 
representatives) also exceeded the minimal median nucleotide divergence between 167 
phylogroups. Furthermore, 4 of the 7 MLST genes (gki, gtr, mutS, and recP) were identified 168 
to have evidence of homologous recombination within their evolutionary history while 169 
another MLST gene (yqiL) is not part of the core GAS genome (Supplementary Table 3 and 170 
4). Collectively, these data suggest that emm-type and MLST may have limited capacity for 171 
assigning evolutionary relationships within a globally evolving population.  172 
 173 
The identification of hundreds of distinct genetic lineages (250 phylogroups) represents a 174 
challenge to unravelling the microevolution of dynamically evolving pathogenic populations. 175 
Indeed, only 23 of the phylogroups identified in this study contain a complete GAS reference 176 
genome (n = 47). Furthermore, the vast majority of publicly available GAS reference 177 
genomes are of strains and emm-types from North America and Europe, with very few 178 
reference types from high-disease burden geographical regions. Moreover, the emm-types 179 
circulating in these high-burden settings are often rarely encountered within high-income 180 
regions.  To enable future research into global to regional GAS population and evolutionary 181 
dynamics, 30 isolates representing geographically and genetically distinct samples were 182 
completely sequenced using the long-read PacBio platform.  The average size of these new 183 
reference genomes was 1,810,671 bp (ranging from 1,701,466 bp to 1,950,606) with 5 strains 184 
containing circular plasmids ranging from 2,645 bp to 6,485 bp in size (Supplementary Table 185 
9). Based on our estimated structure of the global GAS population, these reference genomes 186 
represent 29 previously unsampled phylogroups (Fig. 1a).  These high quality geographically, 187 
clinically and evolutionary diverse genomes will act as an important reference tool for 188 
vaccine developers, microbiologists, and molecular biologists for new studies into the context 189 
of global GAS genome evolution, transmission and disease signatures. 190 
 191 
Analysis of the variable gene content (defined as genes present in less than 99% of the 1,579 192 
genomes) identified 4,838 ‘accessory’ genes when homologues were clustered at a 193 
conservative 70% amino acid identity (average of 308 genes per genome). Plotting of unique 194 
protein counts per new genome added shows that GAS has an ‘open’ pangenome (Fig. 1b), 195 
indicating that further genes will continue to be identified as new GAS genomes are 196 
sequenced. Annotation of the accessory genome derived from prophage analysis of the draft 197 
genome assemblies estimated ~50% of the accessory gene pool of GAS to be phage related. 198 
Plotting of the accessory content relative to the core genome phylogenetic structure of the 199 
global population revealed extensive variation both in total overall and prophage content 200 
within and between GAS core genome lineages (Supplementary Fig. 7), in-line with 201 
observations from GAS microevolutionary analyses19-22. Collectively, this high level of 202 
heterogeneity both in the context of core genome sequence and accessory gene content 203 
provides a unique database for the examination of conservation or sequence variation within 204 
GAS proteins such as vaccine antigens. 205 
 206 
GAS vaccine target variation 207 
To examine natural variation of proposed GAS vaccine antigens within this genetically 208 
diverse GAS population, antigen carriage (gene presence/absence) and amino acid sequence 209 
variation of 29 proteinaceous GAS antigens, including 4 peptide fragments, was determined 210 
(Supplementary Table 1). The list of identified vaccine antigens analysed in this study have 211 
all been shown to convey protection in various murine models (reviewed by Henningham et 212 
al.6) but little is known about the conservation of these antigens within the global GAS 213 
population. Applying a sequence homology-based screening approach to the 1,579 GAS 214 
genome assemblies, 15 antigen genes were identified in >99% of isolates (Fig. 2a) at a 70% 215 
BlastN cut-off. The species defining marker and vaccine candidate group A carbohydrate is 216 
comprised of a 12 gene biosynthesis cluster13. 1,554 GAS genomes (98%) shared all 12 genes 217 
with high DNA sequence conservation. Some genomes harboured frameshift mutations in 218 
several gac genes suggesting that not all 12 genes are critical for GAS survival, 219 
commensurate with previous findings on 520 gac loci23. 220 
 221 
In addition to being omnipresent within the GAS population, an ideal GAS vaccine candidate 222 
would exhibit low levels of naturally occurring sequence variation within a genetically 223 
diverse dataset. To examine this question, pairwise BlastP cut-off values for 25 protein 224 
antigens were calculated. Eighteen antigens exhibited low levels (<2%) of amino-acid 225 
sequence variation (Supplementary Fig. 8). When plotted relative to overall carriage within 226 
1,579 genomes, 14 of the 25 antigens were not only carried by >99% of the 1,579 genome 227 
sequences but also exhibited low levels of allelic variation (<2% sequence divergence) (Fig. 228 
2b, Supplementary Fig. 8). Furthermore, 11 of these 14 core genome vaccine antigens were 229 
identified to have signatures of homologous recombination in their evolutionary history 230 
(Supplementary Fig. 9), emphasising that the evolution of ‘core’ GAS antigens is likely to be 231 
an ongoing process.  232 
 233 
The highest level of sequence heterogeneity was observed with the M-protein. Collectively 234 
28% of genomes had an N-terminal emm type represented within the 30-valent M-protein 235 
vaccine formulation24 (Fig. 2a). We also examined the prevalence of other GAS peptide-236 
based vaccine antigens, namely the C-terminal M-protein sequences of J825 and 237 
StreptInCor26; and the S2 peptide from the serine protease SpyCEP27. Given conformational 238 
and binding constraints afforded by peptide vaccine antigens relative to the complete protein 239 
antigens investigated above, carriage of these peptide antigens were assessed at an exact 240 
100% match with the query peptide sequence within the 1,579 GAS genomes. 37% of the 241 
1,579 isolates harboured the J8.0 allele of the M-protein; 22% carry the conserved 242 
overlapping B and T cell epitope of the StreptInCor M-protein vaccine candidate; and 54% of 243 
isolates encode the S2 peptide from SpyCEP protein. Further interrogation of known J8 244 
sequence variants within the multi-copy M- and M-like C-repeat sequences represented in the 245 
1,579 genome assemblies identified carriage of J8.12 (90%) and J8.40 (80%) to be the most 246 
frequently encountered variants (Supplementary Fig. 10).  247 
 248 
Antigenic heterogeneity within GAS vaccine antigens 249 
Structural analysis of antigens through protein crystallography yields key insights regarding 250 
the identification of key functional amino acid residues and juxtaposition of surface peptide 251 
sequences. The ascertainment of antigenic variation within genome sequence databases 252 
allows such data to be overlaid onto protein structures, yielding important insight regarding 253 
potential sites of structural plasticity or immunodominance, that in turn can be used to inform 254 
vaccine design through identification of invariant surface regions and/or structurally 255 
constrained domains or subdomains. Two crystal structures are publically available for GAS 256 
proteins that fulfil the criteria of global vaccine antigen coverage as defined in this study 257 
(>98% carriage and <2% amino acid sequence variation), Streptolysin O28 and C5a 258 
peptidase29. Identification of polymorphism location and polymorphism frequency within the 259 
1,579 GAS genomes for the Streptolysin O (Fig. 3a, Supplementary Table 5) and C5a 260 
peptidase (Fig. 3a, Supplementary Table 6) proteins were determined. Using this data, we 261 
derived the consensus amino acid sequence for each protein. We then modelled the consensus 262 
sequence and population derived polymorphisms onto the corresponding crystal structures of 263 
the mature Streptolysin O protein (amino acids 103-501, Fig. 3b,c)28 and C5a peptidase 264 
(amino acids 97-1032; Fig. 3b, d)29. Further examination of amino acid heterogeneity present 265 
in at least 10% of the 1,579 genomes within the mature Streptolysin O protein, revealed 5 266 
sequence diversity hotspots (Fig. 3c, Supplementary Table 7). All polymorphisms were 267 
bimorphic in nature indicating restrictions in Streptolysin O plasticity (Supplementary Table 268 
7). In comparison, we identified 20 sequence diversity hotspots within the mature C5a 269 
peptidase protein of which half were bimorphic (Fig. 3a, Supplementary Table 8), indicating 270 
more plasticity can be accommodated within the C5a peptidase than Streptolysin O. To 271 
ascertain the functional consequence of the most common protein variations, we examined 272 
mutational sensitivity and structural integrity of these amino acids variants using Phyre230 273 
and the SuSPect platform31.  All substitutions in both Streptolysin O and C5a peptidase were 274 
at locations where it was predicted that a change to any amino acid would not impact protein 275 
structure or activity (Supplementary Tables 7 and 8). Such variation may reflect immune 276 
selection and/or the amount of plasticity that can be encompassed without compromising 277 
protein function.  278 
 279 
DISCUSSION 280 
 281 
There is a strong case for the development of a safe and efficacious GAS vaccine1,2. One of 282 
several hurdles to be addressed in the development of a GAS vaccine suitable for worldwide 283 
use is the extensive genetic diversity of the global GAS population. To address issues of 284 
vaccine antigen gene carriage within the global GAS population and the extensive variation 285 
of antigen amino acid sequences between isolates, we have developed a platform for the 286 
interrogation of candidate antigens at unprecedented resolution. We have demonstrated that 287 
GAS is a genetically diverse species containing a large dispensable gene pool. Within the 288 
core or ‘conserved’ genome we have identified extensive evidence of recombination that will 289 
initiate future research into the drivers and biology of such dynamic evolution. This diversity 290 
also has consequences for vaccine induced evolutionary sweeps of bacterial populations and 291 
subsequent emergence of vaccine escape clones, as has been observed in targeted 292 
Streptococcus pneumoniae32 and Bordetella pertussis33 vaccination programs.  293 
 294 
The generation of high quality, well curated reference genomes acts as a landmark for 295 
understanding the evolutionary context of a species, especially given the high levels of 296 
genetic diversity encountered in bacterial populations such as GAS and the contrasting 297 
epidemiology of infection observed between high-income countries and less-developed 298 
economic regions of the world where the overwhelming burden of GAS disease resides. The 299 
availability of new GAS reference genomes enable targeted evolutionary and pathobiological 300 
studies of this genetically diverse pathogen. The 30 new GAS reference genomes reveal that 301 
despite an open pangenome where accessory gene content varies significantly across the 302 
population and recombination appears frequent, the overall size of the GAS genome remains 303 
at a steady state. Only recently have plasmids been identified within the GAS genome34. We 304 
have identified a further 5 small plasmids in GAS ranging in size from 2,645 bp to 6,485 bp, 305 
harbouring bacteriocin like genetic markers that are suggested to play a role in inter-bacterial 306 
inhibition35. In the context of vaccination, the availability of a globally representative 307 
reference database will provide a platform for examining the effect of future vaccination 308 
programs32,33.   309 
 310 
Modelling of population based antigenic variation against protein crystal structures enables 311 
the identification of residues that may be under functional or structural constraints, or 312 
alternatively, selection pressure. This population-derived sequence approach could be 313 
assessed alongside immunological studies to define protective epitopes. Such information can 314 
be incorporated into further refinement of vaccine antigens such as peptide-based approaches 315 
that factor in naturally occurring population heterogeneity enabling the targeting of 316 
immunogenic epitopes within antigens that are less amenable to variation.  317 
 318 
This platform for population genomics-informed vaccine design is equally applicable to all 319 
known GAS antigens and those that remain to be discovered. Thus, informed selection of 320 
putative vaccine antigens will now be possible, allowing identification of highly conserved 321 
antigens or combinations of antigens that ensure complete vaccine coverage across GAS emm 322 
types from differing geographic regions. An approach similar to that used in this study would 323 
also be applicable to other pathogens that exhibit high levels of global strain diversity. 324 
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FIGURE LEGENDS 444 
 445 
Figure 1. Population structure and pangenome of 1,579 globally distributed GAS strains. (a) 446 
Maximum-likelihood phylogenetic tree of 33,917 SNPs generated from an alignment of 484 447 
core genes. Branch colours indicate bootstrap support according to the legend. Distinct 448 
genetic lineages (n=250) are highlighted in alternating colours (blue and grey) from the tips 449 
of the tree. Coloured asterisks refer to the relative position of complete GAS reference 450 
genome sequences (existing references are shown in brown; 30 new reference genomes are 451 
shown in blue). Colour coded around the outside of the phylogenetic tree is the country of 452 
isolation for each isolate. (b) Pangenome accumulation curve of 1,579 GAS genomes based 453 
on clustering of protein sequence at 70% homology.  454 
 455 
Figure 2. Antigenic variation within vaccine targets from 1,579 GAS genomes. (a) Gene 456 
carriage (presence/absence) of vaccine antigens. (b) Amino acid sequence variation within 25 457 
protein antigens for each of the GAS1579 genomes. Each ring represents a single antigen 458 
with protein similarity colour coded according to pairwise BlastP similarity: Black (>98%); 459 
Blue (between 95 – 98%); Red (between 90 - 95%); Pink (80 - 90%); Yellow (70 - 80%); 460 
Grey (< 70%); and White (protein absence). Rings correspond to: 1) R28; 2) Sfb1; 3) Spa; 4) 461 
SfbII; 5) FbaA; 6) SpeA; 7) M1 (whole protein); (8) M1 (180bp N-terminal) 9) SpeC; 10) 462 
Sse; 11) Sib35; 12) ScpA; 13) SpyCEP; 14) PulA; 15) SLO; 16) Shr; 17) OppA; 18) SpeB; 463 
19) Fbp54; 20) SpyAD; 21) Spy0651; 22) Spy0762; 23) Spy0942; 24) ADI; and 25) TF 464 
 465 
Figure 3. Global amino acid variation mapped onto the protein crystal structure of the mature 466 
GAS Streptolysin O28 and C5a peptidase29.  (a) Frequency of amino acid variations within 467 
1,579 genomes. (b) Schematic of the Streptolysin O and C5a peptidase open reading frame 468 
representing the location of amino acids within the mature enzymes (blue block). Model of 469 
the consensus sequence of the Streptolysin O (c) and C5a peptidase (d) mature enzymes. 470 
Plotted against the structure is the amino acid variation frequency within the 1,579 GAS 471 
genomes as represented in the colour gradient from 1% variable (blue) to 42% variable (red); 472 
invariant sites are coloured in light grey. Position of the top 5 most variable surface hotspots 473 
(“HS”) are annotated (as defined in Supplementary Tables 7 and 8). Active sites for each 474 
enzyme are indicated (cyan).  475 
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